Clinical trials: Treatment naïve
Chronic Hepatitis C
Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)
The objective of the study is to select an optimal dose of taribavirin by comparing the efficacy and safety of 3 taribavirin dose levels, 20, 25, and 30 mg/kg/day, versus ribavirin 800 to 1400 mg/day based on body weight, both…
- Trial name
- NCT00446134
- Testing
- Taribavirin, Ribavirin
- Where
- United States
- Volunteers
- 278 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Genotype 1a or 1b HCV Infection
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects…
- Trial name
- NCT01434498
- Testing
- GS-5885 tablet, GS-9451 tablet, tegobuvir capsule
- Where
- 50 sites in United States, Canada and 1 more
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
Neovascular Age-related Macular Degeneration
A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).
In people with neovascular age-related macular degeneration (nAMD), the body makes too much of a protein called vascular endothelial growth factor (VEGF).
- Trial name
- BELUGA (NCT04641234)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Belgium
- Volunteers
- 330 people
- Sponsor
- Bayer
Hematology, Diffused Large B Cell Lymphoma
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy, with over 80,500 estimated new cases diagnosed in the United States in 20231.
- Trial name
- DOMAIN (NCT07065344)
- Where
- 21 sites in Egypt, Iraq and 8 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Metastatic Non Small Cell Lung Cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer…
- Trial name
- TROPION-Lung08 (NCT05215340)
- Testing
- Datopotamab Deruxtecan, Pembrolizumab
- Where
- 234 sites in United States, Argentina and 26 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo
Hepatitis C, Chronic
Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)
This is a controlled, randomized, parallel-groups, open-label, multinational study designed to evaluate the efficacy and safety of PEG-Intron® (pegylated interferon alfa-2b) plus Rebetol® (ribavirin) in subjects with chronic…
- Trial name
- NCT00265395
- Testing
- Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®), Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 1,428 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no…
- Trial name
- LEAP-007 (NCT04676412)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 17 sites in China
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects with Chronic Hepatitis C Virus…
- Trial name
- NCT01316237
- Testing
- GS-6620, GS-6620 tablet, 450 mg BID, GS-6620 tablet
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- Gilead Sciences
Myelodysplastic Syndrome, Anemia
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
The main aim of this study is to assess how much elritercept reduces the need for RBC (red blood cell) transfusions and improves hemoglobin blood values in addition to how safe elritercept is when compared with epoetin alfa.
- Trial name
- ELRiSE MDS (NCT07422480)
- Testing
- Elritercept, Epoetin Alfa
- Where
- 162 sites in United States, Argentina and 26 more
- Volunteers
- 300 people
- Sponsor
- Takeda
Hepatitis C
Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive
The purpose of this study is to test the hypothesis that clemizole hydrochloride is safe and well tolerated when administered to subjects who are infected with hepatitis C virus and have not yet received treatment.
- Trial name
- CLEAN-1 (NCT00945880)
- Testing
- clemizole hydrochloride
- Volunteers
- 12 people
- Sponsor
- Eiger BioPharmaceuticals
Open-angle Glaucoma
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost
Evaluation of the intraocular pressure (IOP) lowering effect of two iStent devices versus medical therapy in eyes of subjects with primary open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to medical…
- Trial name
- NCT01443988
- Testing
- iStent, Travoprost
- Where
- Armenia
- Volunteers
- 101 people
- Sponsor
- Glaukos Corporation
HIV
Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia
One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy.
- Trial name
- NCT01275625
- Testing
- HIV therapy
- Where
- 8 sites in Russia
- Volunteers
- 98 people
- Sponsor
- ViiV Healthcare
Diabetes Mellitus, Type 2
Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients
Primary Objective: To determine the superiority of glimepiride over sitagliptin in the reduction of HbA1c after 6 months of treatment in patients with monotherapy until the end of the trial.
- Trial name
- SUMER (NCT00957060)
- Testing
- GLIMEPIRIDE (HOE490), SITAGLIPTIN
- Where
- 2 sites in Guatemala, Mexico
- Volunteers
- 400 people
- Sponsor
- Sanofi
Atrial Fibrillation
Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation
The purpose of the study is to collect additional information of Xarelto treatment in routine clinical practice. Patients affected by atrial fibrillation and who will get Xarelto as a prophylactic treatment against stroke and…
- Trial name
- XaMINA (NCT03284762)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 2 sites in South Korea, Taiwan
- Volunteers
- 1,216 people
- Sponsor
- Bayer
Hepatitis C, Chronic
Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir given in combination with pegylated interferon alfa-2b (peg-IFN) and ribavirin (RBV) versus treatment with peg-IFN and RBV alone in…
- Trial name
- NCT01370642
- Testing
- vaniprevir, Peg-IFN, ribavirin
- Volunteers
- 294 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed/Refractory Multiple Myeloma
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
This was a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma…
- Trial name
- Bellini (NCT02755597)
- Testing
- Venetoclax, Bortezomib, Dexamethasone
- Where
- 97 sites in United States, Australia and 14 more
- Volunteers
- 291 people
- Sponsor
- AbbVie
Prostate Cancer
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen…
- Trial name
- PREVAIL (NCT01212991)
- Testing
- Enzalutamide
- Where
- 269 sites in United States, Australia and 20 more
- Volunteers
- 1,717 people
- Sponsor
- Pfizer
Arthritis, Psoriatic
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
This study is undertaken to compare the efficacy and onset of action of infliximab plus methotrexate (IFX + MTX) versus methotrexate alone (MTX) in methotrexate naïve active psoriatic arthritis patients.
- Trial name
- NCT00367237
- Testing
- Infliximab + methotrexate (IFX + MTX), Methotrexate (MTX)
- Volunteers
- 115 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Virus (HCV)
ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
This is a Phase 3, open-label, multicenter study evaluating the efficacy and safety of ABT-450/r/ ABT-267 and ABT-333 coadministered with RBV for 12 weeks in HCV genotype 1b, treatment naïve and Interferon (IFN) (alpha, beta or…
- Trial name
- NCT02517528
- Testing
- ABT-450/r/ABT-267, ABT-333, ribavirin
- Volunteers
- 104 people
- Sponsor
- AbbVie
HCV (Genotype 1)
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
The purpose of this study is to determine the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects.
- Trial name
- NCT01250366
- Testing
- INX-08189, Ribavirin
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb